Harbour BioMed gets FDA nod to begin clinical trial for HBM4003 in cancer

Harbour BioMed gets FDA nod to begin clinical trial for HBM4003 in cancer

Source: 
Pharmaceutical Business Review
snippet: 

Harbour BioMed has secured approval from the US Food and Drug Administration (FDA) to move ahead with clinical studies in the US for its anti-CTLA-4 antibody HBM4003 for the treatment of cancer.